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AbsTrACT
Objectives This study aimed to explore the effects 
of an isocaloric Mediterranean diet (MD) intervention 
on metabolic health, gut microbiome and systemic 
metabolome in subjects with lifestyle risk factors for 
metabolic disease.
Design eighty- two healthy overweight and obese 
subjects with a habitually low intake of fruit and 
vegetables and a sedentary lifestyle participated in a 
parallel 8- week randomised controlled trial. Forty- three 
participants consumed an MD tailored to their habitual 
energy intakes (MedD), and 39 maintained their regular 
diets (conD). Dietary adherence, metabolic parameters, 
gut microbiome and systemic metabolome were 
monitored over the study period.
results increased MD adherence in the MedD group 
successfully reprogrammed subjects’ intake of fibre and 
animal proteins. compliance was confirmed by lowered 
levels of carnitine in plasma and urine. significant 
reductions in plasma cholesterol (primary outcome) 
and faecal bile acids occurred in the MedD compared 
with the conD group. shotgun metagenomics showed 
gut microbiome changes that reflected individual 
MD adherence and increase in gene richness in 
participants who reduced systemic inflammation over the 
intervention. The MD intervention led to increased levels 
of the fibre- degrading Faecalibacterium prausnitzii and 
of genes for microbial carbohydrate degradation linked 
to butyrate metabolism. The dietary changes in the MedD 
group led to increased urinary urolithins, faecal bile acid 
degradation and insulin sensitivity that co- varied with 
specific microbial taxa.
Conclusion switching subjects to an MD while 
maintaining their energy intake reduced their blood 
cholesterol and caused multiple changes in their 
microbiome and metabolome that are relevant in future 
strategies for the improvement of metabolic health.
InTrODuCTIOn
Diet is a fundamental factor affecting gut health. 
Mounting evidence highlights that diets richer in 
plant- based rather than animal- based foods could 
represent healthier choices to prevent disease.1 2 
The Mediterranean diet (MD) is a recommended 
nutritional pattern with evidence of beneficial 
effects including the prevention of several types of 
disease, such as cardiovascular disease (CVD), type 
significance of this study
What is already known about this subject?
 ► Diet fundamentally influences gut health.
 ► Mediterranean diet (MD) is a recommended 
nutritional pattern with known beneficial 
effects including the prevention of several types 
of disease.
 ► Current knowledge of the effect of diet on 
microbiome- mediated health outcomes in 
humans relies mainly on observational studies.
What are the new findings?
 ► An isocaloric 8- week intervention with an MD 
in obese and overweight subjects leads to a 
decrease in total, low- density lipoprotein and 
high- density lipoprotein plasma cholesterol 
and faecal bile acids levels independently of 
energy intake, the decrease in cholesterol being 
proportional to MD adherence rates.
 ► The MD intervention causes microbiome 
changes with increased gene richness in 
individuals with reduced inflammation, a rise in 
the fibre- degrading Faecalibacterium prausnitzii 
accompanied by a decrease of the potentially 
proinflammatory Ruminococcus gnavus.
 ► Increased MD adherence generates consistent 
metabolome changes, with lower plasma and 
urinary carnitine levels and protein degradation 
products concomitant with the increase of 
dietary biomarkers of plant- based foods.
 ► The consumption of plant foods typical of 
an MD can determine increase in urolithin 
production, decreased insulin resistance and 
bile acid levels, and such changes are all 
consistently related to baseline levels and 
variations of the microbial species involved in 
these specific metabolic features.
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significance of this study
How might it impact on clinical practice in the foreseeable 
future?
 ► The results of this study clearly show that a change in dietary 
behaviour without any concomitant change in individual 
energy intake, macronutrient intake and physical activity 
can lower blood cholesterol, already after 4 weeks, in a 
population with cardiometabolic risk for unhealthy lifestyle.
 ► The beneficial dietary changes are in line with an increased 
adherence to MD and include a reduction of intake of meat 
and refined cereal products and increased intakes of fruit, 
vegetables, wholegrain cereal products, legumes and fish, 
along with a daily consumption of nuts.
 ► Some individuals harbour a gut microbiome that is more 
susceptible to MD- induced changes and experience further 
clinical advantages such as amelioration of insulin sensitivity 
and of inflammatory status.
2 diabetes, obesity, inflammatory diseases, degenerative diseases 
and cancer.3–5
The microbiome partly but significantly affects individual 
metabolism and how one responds to changes in dietary habits.6 7 
Host health is influenced by microbiome composition and by 
microbial metabolites that can be produced from host metabolic 
intermediates or from dietary precursors.8 Therefore, current 
trends in personalised nutrition suggest that diet can be used to 
modulate microbiome composition and function.9 10 Indeed, the 
production of beneficial microbial metabolites can be increased, 
and the production of detrimental metabolites can be reduced by 
modulating nutrient intake and supplying a beneficial pattern of 
key precursors to the microbiome.
The current knowledge of the role of diet on microbiome- 
mediated health outcomes in humans mainly relies on obser-
vational studies in which confounding factors affect the 
conclusions.11 Intervention studies to address the causal effects 
of diet on microbiome functions are still scarce or have been 
performed in animal models,12 and this lack of knowledge also 
applies to the MD.13 Despite their cost and labour- intensiveness, 
randomised controlled trials (RCTs) are the gold standard for 
evidence- based medicine and are an appropriate tool for iden-
tifying a causal relationship of a specific nutrient or diet on a 
health outcome in humans.14 15
A Western diet is characterised by an excessive intake of foods 
with a high energy density and that are rich in fats, sugars and 
animal proteins, as well as a very low intake of fruits and vegeta-
bles. Such a dietary style, accompanied by low levels of physical 
activity, promotes inflammation16 and predisposes individuals 
to obesity, CVD, type 2 diabetes and metabolic syndrome.17 18 
Because obesity is highly prevalent worldwide and is recognised 
as an independent risk factor for metabolic- driven chronic 
diseases, efforts need to be made urgently to provide evidence- 
based recommendations for healthy dietary patterns.
The aim of this study was to evaluate the effect of an individ-
ually tailored MD intervention in subjects at increased risk of 
cardiovascular disease.
MATerIAls AnD MeTHODs
study design and population
We investigated the gut microbiome, faecal, blood and urinary 
metabolomic profiles in 82 overweight/obese subjects in response 
to an 8- week isocaloric dietary intervention with an MD or 
a control diet. Each participant provided written informed 
consent and received no financial compensation. The trial was 
registered at  ClinicalTrials. gov (number NCT03071718). The 
protocol ended when the last group of participants completed 
the protocol (Study Start Date: June 2016; Actual Primary 
Completion Date: July 2017; Actual Study Completion Date: 
February 2019).
The study design, selection criteria and participant flow 
throughout the study are reported in the online supplemen-
tary materials (online supplementary figure 1). Plasma lipids 
(including plasma cholesterol and triglycerides) and faecal levels 
of short- chain fatty acids (SCFAs) were registered as primary 
outcomes of the study, while changes in gut microbiota and 
some intermediate markers of metabolic disease, such as blood 
pressure, fasting blood glucose, serum high sensitivity C reac-
tive protein (hs- CRP), urinary and plasma trimethylamine oxide 
(TMAO), plasma gastrointestinal peptides and urinary polyphe-
nols, were secondary outcomes (detection methods described 
in the online supplementary material). Briefly, 334 potentially 
eligible adults were screened on the basis of the inclusion/exclu-
sion criteria, including medical and lifestyle conditions (ie, 
habitual diet and physical activity) (detailed criteria are in the 
online supplementary material). Adherence to the MD was esti-
mated by using the 11- unit dietary score and is reported as the 
Italian Mediterranean Index (MD index).19
Eighty- two subjects (43 female and 39 male, average body 
mass index (BMI) 31.1±4.5 kg/m2, age 43±12 years, further 
baseline features in the online supplementary table 1) were 
selected, enrolled and randomised between the two intervention 
arms of the parallel study design, that is, MedD or ConD.
Dietary intervention
Each participant in the MedD group consumed an individually 
tailored diet that maintained the daily energy and macronutrient 
intake of the habitual diet and guaranteed a dietary pattern 
typical of the MD. Participants in the ConD group were asked 
to maintain their habitual diet. Individual compliance with the 
protocol was assessed every 2 weeks by self- recorded 7- day food 
diaries and physical activity questionnaires. Visits and sample 
collection were performed at baseline, 4 weeks and 8 weeks (full 
details reported in the online supplementary material).
Metabolomics
Untargeted urine, serum and faeces metabolomics,20 21 as well 
as targeted quantification of bile acids (BAs) and SCFAs in the 
faeces,22 23 were performed by ultra- high- performance liquid 
chromatography mass spectrometry. Trimethylamine N- oxide 
(TMAO), carnitine, choline, creatinine, betaine in plasma and 
urine, as well as urinary urolithins, were also determined by 
targeted metabolomics using liquid chromatography tandem 
mass spectrometry. Details are available in the online supplemen-
tary material and online supplementary tables 2–3.
Metagenomics
A full description of the sampling, sequencing and data analysis 
procedures is reported in the online supplementary material. 
DNA libraries were sequenced using the Ion Proton Sequencer 
(ThermoFisher Scientific, Waltham, USA), with a minimum 
of 20 million 150 bp high- quality reads generated per library. 
Metagenomic species pangenome (MSP)24 was used to iden-
tify and quantify species associated with the 9.9- million- gene 
integrated reference catalogue. The functional potentials of the 
intestinal gut microbiota were determined by using the in- house 
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Figure 1 Adherence to the Mediterranean diet (MD) and changes in dietary and metabolic variables. (A) Box plots showing MD index score for 
controls (ConD) or treated subjects (MedD) during the intervention, the significance was tested by applying the post hoc Friedman- Nemenyi test 
for pairwise test of multiple comparisons within each group. (B) Percentage changes in dietary and metabolic variables are represented as spider 
chart. Changes in levels of dietary components consumption including (C) dietary fibre, (D) vegetable proteins/animal proteins ratio, (E) saturated 
to polyunsaturated fats ratio. Reduction in serum and urinary markers such as (F) plasma carnitine, (G) urinary carnitine and (H) total cholesterol. 
The significance was tested by applying unpaired Wilcoxon rank- sum tests for variation at the specific time point compared with baseline in MedD 
versus ConD. Orange boxes refer to controls and green boxes to Mediterranean subjects, respectively. Baseline, 0 weeks; 4w, 4 weeks; 8w, 8 weeks of 
nutritional intervention (*p<0.05, **p<0.01 and ***p<0.001).
FAnToMet pipeline as described in the online supplementary 
material.
statistical analysis
Statistical analysis and visualisation were carried out in R 
environment V.3.4.2 (https://www. r- project. org). ggpubr and 
PMCMR R packages were used to assess significant differences. 
Variations in dietary and clinical variables at specific time points 
compared with baseline values between the MedD and ConD 
groups were evaluated by two- way analysis of variance with 
repeated measures and Tukey’s post hoc test. Non- parametric 
Wilcoxon signed- rank test (testRelations function of momr R 
package) was performed to compare means between ConD and 
MedD subjects at each time point, while the post hoc Nemenyi 
test for multiple comparisons following the Friedman test was 
used within each group.
Pairwise Spearman’s rank correlations were used to estimate 
the overall similarity of the microbiome and metabolome within 
the MedD and ConD groups and between time points (baseline 
vs 4 weeks and 4 weeks vs 8 weeks). The same test was applied to 
the microbiome, dietary variables, clinical markers and targeted 
metabolome datasets. Adjustments were performed using the 
Benjamini- Hochberg procedure. Correlations were visualised 
using the ComplexHeatmap package.25
Machine learning- based classification26 of metabolomics 
data and further details on data analysis and visualisation are 
provided in the online supplementary material.
Patient and public involvement
Patient and public involvement was not considered in this 
research.
Data availability
Metagenomic reads generated in this study are available (without 
conditions of reuse) under the accession number PRJEB33500 at 
the European Nucleotide Archive (ENA) in EBI (https://www. 
ebi. ac. uk/ ena/ data/ view/ PRJEB33500).
resulTs
MD lowered plasma cholesterol in the overall population
No significant differences in anthropometric measures or clinical 
variables monitored in blood and urine samples were observed 
between the ConD (n=39) and MedD (n=43) groups at baseline 
(online supplementary table 1). Regarding the primary outcomes, 
as a consequence of the intervention, the participants in the 
MedD showed a significant decrease in total plasma cholesterol 
(figure 1) and high- density lipoprotein (HDL)- cholesterol after 
4 weeks compared with the ConD group (online supplementary 
table 1). No changes in any of the secondary outcomes such as 
blood glucose, serum hs- CRP, plasma insulin, TMAO or any 
intermediate markers of metabolic disease (glucagon, ghrelin, 
GIP, GLP-1, leptin, C- peptide, resistin, visfatin and PAI-1) were 
observed (online supplementary table 1).
Successful compliance to the protocol and cholesterol decrease 
proportional to MD adherence rates
Adherence to the MD significantly increased in the MedD group 
at 4 and 8 weeks compared with the baseline (figure 1A) and was 
highly correlated with the Healthy Food Diversity (HFD) index27 
(online supplementary figure 2). Significant percentage changes 
in dietary and metabolic variables are shown in figure 1B. Partic-
ipants in the MedD group significantly increased their daily 
intake of dietary fibre by twofold and their dietary vegetable:-
animal protein ratio by 2.5- fold over the intervention compared 
with the ConD group (p<0.001, figure 1C,D). A significant 
reduction in saturated fat intake and an increase in polyunsatu-
rated fat intake was also achieved (p<0.001, figure 1E). These 
changes in nutrient intake in the MedD versus the ConD group 
were due to increased consumption of fruits, vegetables, nuts, 
wholegrain cereals and fish products concurrent with reduced 
consumption of refined cereals, dairy and meat products. The 
reduced consumption of meat products was confirmed by the 
reduction of the dietary intake biomarker of these foods in the 
MedD versus ConD group, that is, the concentration of carnitine 
in the plasma (14% and 11% reductions after 4 and 8 weeks, 
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Figure 2 Mediterranean diet changes the intestinal and systemic metabolome. Partial least squares discriminant analysis plots based on molecular 
features detected in (A) faeces and (B) urine. Subjects belonging to different categories were coloured according to diet and time points: MedD 
subjects at baseline (light green), after 4 weeks (green) and 8 weeks of intervention (dark green). ConD subjects at baseline (light orange), after 4 
weeks (orange) and 8 weeks (dark orange) of intervention. The loading plots display vectors that contributed the most to variability of individual 
dataset; variables explaining the variance between the groups in (C) faecal and (D) urine metabolome are reported as bar plots.
p<0.05 and p<0.001, respectively, figure 1F) and urine (75% 
and 51% reductions after 4 and 8 weeks, p<0.01 and p<0.001, 
respectively, figure 1G).
During the run- in period, some subjects (12 in the MedD 
group and 6 in the ConD group) undesirably increased their 
intake of fruit and vegetables above three servings/day compared 
with their consumption at the time of enrolment. We decided 
to strictly focus on the population who maintained a baseline 
dietary intake of fruits and vegetables <3 servings/day. In addi-
tion, two subjects were not considered because not all the faecal 
samples were available. Therefore, the subsequent data analyses 
were carried out with a subgroup of 62 subjects, 32 in the ConD 
group and 30 in the MedD group. High compliance with the 
intervention was confirmed in both groups. Changes in dietary 
intake of nutrients from several food categories are shown in 
online supplementary figure 3. The effect of MedD on plasma 
cholesterol was confirmed in this subgroup. Indeed, following 
4 weeks of intervention with an MD, a significant reduction 
(p=0.03) in plasma LDL- cholesterol from 2.90±0.13 mmol/L 
at baseline to 2.66±0.12 mmol/L at 4 weeks was observed in 
the MedD group compared with the change in the ConD group 
(3.24±0.13 mmol/L at baseline to 3.25±0.12 mmol/L at 4 weeks), 
and a significant reduction (p=0.02) in plasma HDL- cholesterol 
from 1.26±0.05 mmol/L at baseline to 1.18±0.04 mmol/L at 
4 weeks was observed in the MedD group compared with the 
change in the ConD group (1.21±0.05 mmol/L at baseline to 
1.25±0.05 mmol/L at 4 weeks).
Interestingly, decrease in cholesterol levels was proportional 
to MD adherence rate. By applying a linear model, it was found 
that each unit increase in the MD index corresponded to ≃2% 
reduction in total plasma cholesterol (p=0.003, online supple-
mentary figure 4), a 2% reduction in plasma LDL- cholesterol 
(p=0.01) and 1% reduction in plasma HDL- cholesterol 
(p=0.04) after adjustment for age, sex, BMI and energy intake.
Diet-induced metabolome changes with release of biomarkers of 
MD consumption
We measured approximately 11 000 molecular features in all 
our participants during the intervention (2200 in faeces, 4125 
in blood and 4645 in urine). A list of annotated metabolites 
is provided in online supplementary table 4 and the evidence 
substantiating the annotation of diet- responsive metabolites is 
provided in online supplementary material (online supplemen-
tary figures 5–25). Clear shifts in the metabolomic profiles were 
observed in the MedD group after the intervention compared 
with the baseline conditions and the ConD group (figure 2). 
Decreasing Spearman’s correlation coefficients (4 weeks vs 
baseline; 8 weeks vs baseline) indicated a significant change 
in the urine metabolic profiles after 4 (p=0.01) and 8 weeks 
(p=0.01) of intervention in the MedD group versus the ConD 
group. In order to validate the robustness of the shifts observed, 
we used a machine learning- based classification approach26 
(area under the curve (AUC)=0.88 and 0.87 between the ConD 
and MedD groups at 4 and 8 weeks, respectively; as a control, 
AUC=0.52 was observed at baseline), which supported the 
metabolome changes found. In agreement with the replacement 
of refined cereal with wholegrain products and the replace-
ment of meat, eggs and dairy products with fishery products, 
legumes and provided nuts, we found increased levels of the 
biomarkers of wholegrains (3-(3,5- dihydroxyphenyl) propanoic 
acid- glucuronide),28 legumes (tryptophan betaine),29 vegeta-
bles/berries (oxindole-3- acetic acid)30 and nuts (urolithins)31 in 
the MedD group, while biomarkers of meat (carnitine),32 BAs, 
leucine and isoleucine were more closely linked to the ConD 
group (figure 2). Notably, no change in urine or serum TMAO 
was observed, possibly due to contrasting effects of increasing 
intake of fish and lowering meat- derived proteins in the MedD 
group.
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Figure 3 Microbial diversity richness anticorrelates with inflammation. (A) Spearman’s correlation between variation of gut microbial gene richness 
and individual inflammatory status (serum hs- CRP) variation at the end of trial; n observation=62. (B) Violin plot showing differences in serum hs- CRP 
variation between subjects increasing (n=25, yellow) compared with subjects decreasing (n=37, light blue) gene richness at the end of trial. Statistical 
differences between groups were determined using unpaired Wilcoxon rank- sum tests. hs- CRP, high sensitivity C reactive protein.
MD- mediated increase in biomarkers of wholegrain (benzox-
azinoids, pipecolic acid betaine), vegetable (oxindole-3- acetic 
acid), legume (tryptophan betaine, pyrogallol- sulfate), nuts 
(urolithins) and fish (3- carboxy-4- methyl-5- propyl-2- furanprop
ionic acid) consumption and decrease in meat (carnitine) and 
protein degradation products such as branched- chain amino 
acids (BCAAs), aromatic amino acids, N- acetylcadaverine and 
microbial- derived proteolysis products (p- cresol sulfate, indoxyl 
sulfate, phenylacetylglutamine) was further confirmed by their 
significant links with the MD index (online supplementary figure 
26). Finally, a range of host- derived short- chain and medium- 
chain acylcarnitines was significantly reduced in the urine 
following the MD intervention, indicating a shift in substrates 
for energy metabolism from fat to complex carbohydrates and 
protein.33
Gut microbiome composition is modulated by adherence to 
the MD
Gene (average=5 551 310.5±120 191) and MSP richness 
(average=230.9±53.1) metrics were maintained during the 
intervention. However, a significant inverse correlation was 
found between the variation in gut microbial gene richness and 
individual inflammatory status evaluated by serum hs- CRP vari-
ations (figure 3A). Subjects showing increased gene richness 
displayed significantly lower levels of serum hs- CRP after 8 
weeks of the dietary intervention (figure 3B).
The increased adherence to the MD in the first 4 weeks corre-
sponded to a decrease in the microbiome similarity in the MedD 
group during the same time interval, suggesting a MD- induced 
rearrangement of the gut microbiome composition (figure 4). 
This change was not observed either in the ConD group over the 
entire intervention or in the MedD group between 4 weeks and 
8 weeks, that is, in intervention conditions when participants did 
not change their adherence to the MD.
While a negligible number of differentially abundant MSPs was 
found at baseline between the ConD and MedD groups (n=27 
MSPs, online supplementary figure 27 and online supplemen-
tary table 5), more contrasting species were observed at 4 (n=77 
MSPs) and 8 weeks (n=44 MSPs, online supplementary figures 
28 and 29, online supplementary table 5), with the proportion 
of contrasting species consistently linked to the MD adherence 
evaluated by MD index (online supplementary tables 5 and 6).
During the increasing MD adherence phase (baseline-4 
weeks), Ruthenibacterium lactatiformans, Flavonifractor plautii, 
Parabacteroides merdae, Ruminococcus torques and Rumino-
coccus gnavus were significantly reduced in the MedD compared 
with the ConD group, along with Streptococcus thermophilus, a 
well- known marker of dairy product consumption. In contrast, 
five members of the Faecalibacterium prausnitzii clade were 
enriched in the MedD compared with the ConD group at either 
4 or 8 weeks (online supplementary tables 5 and 6), along with 
several members of the Roseburia and Lachnospiraceae taxa. 
Consistently, MSPs enriched in the MedD group after 4 weeks 
were significantly linked to MD food biomarkers (online supple-
mentary figure 30).
While only five gut metabolic modules (GMMs) were different 
between the diets (4% of functional potential variation; online 
supplementary table 7) at baseline, 18% variation in the meta-
bolic potential captured by GMM was observed after 4 weeks. 
Several GMMs (n=19) were enriched in the MedD group, 
mainly including pathways related to amino acid and carbohy-
drate degradation. The pathways also included triglyceride and 
glycoprotein degradation and conversion of acetyl- CoA and 
glutamate degradation, both leading to crotonyl- CoA, a possible 
precursor of butyrate metabolism (online supplementary table 
7). Although only 6% variation was observed after 8 weeks, 
enrichment in glutamate degradation to crotonyl- CoA was main-
tained in the MedD group. This pathway was significantly linked 
to the levels of F. prausnitzii msp_0388 (Spearman’s rho=0.73, 
p<10e-6, online supplementary figure 30).
Altogether, by integrating the three meta- omics datasets,34 we 
observed a separation of the ConD and MedD groups on the 
basis of microbiome diversity, functional modules and metab-
olomic profiles (Hotelling T2=40.95, p<7.038e-12; online 
supplementary figure 31) corroborating the changes induced by 
the MD intervention.
MD intervention affects microbiome functions
We measured a number of metabolites associated with gut micro-
bial metabolism to investigate the effect of the MD dietary inter-
vention on health- related microbial activities. Urinary levels of 
urolithin glucuronides increased in the MedD compared with the 
ConD group (table 1). Such increase was consistently linked with 
the levels of urolithin producers in the microbiome, including, 
among others, members of the Eggerthellaceae family (online 
supplementary table 8), and with the consumption of nuts 
that were the sole dietary source of ellagitannins significantly 
increased in the MedD group. Interestingly, urolithin production 
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Figure 4 Mediterranean diet (MD) affects gut microbiome composition. (A) Total delta MD index changes over the 4w- baseline period. Left: 
histograms of delta (4w- baseline) MD index (n=62). Right: linear regressions of microbiome similarity compared with delta 4w- baseline MD index. 
Microbiome similarity was estimated by Spearman correlations between microbial composition at 4 weeks and baseline within each individual. 
(B) Total MD index fractional changes (FCs) (4w- baseline)/baseline, used as proxy to measure the effort of adherence (n=62). Left: distribution of 
individuals relative to MD index FC. Right: linear regressions of microbiome similarity and FC. Spearman correlations (rho and p values) are reported, 
excluding outliers, for ConD (n=31) and MedD (n=26) groups, respectively. 4w, 4 weeks.
Table 1 Urinary urolithins- glucuronides levels (ng/µmol creatinine) detected over the study period
MedD ConD P values
baseline 4 8w baseline 4w 8w Δ(4w – baseline) Δ(8w – baseline)
Urolithin- A- glucuronide 30.8±37.7 139.8±296.8 214.4±358 5.4±30.5 6.9±35.7 5±28.3 0.013 0.025
Urolithin- B- glucuronide 0.1±0.7 21.7±60.6 74.1±243.4 0.2±0.9 0.1±0.5 5.4±30.6 0.0073 0.086
Urolithin- C- glucuronide 1.6±8.8 46.8±107.2 43.2±176.6 0±0 0±0 0±0 0.021 0.16
Total urolithins (A+B+C) 32.6±91.8 208.3±373.8 336.7±594.3 5.5±30.5 7±35.7 10.4±41 0.00034 0.033
Data are expressed as mean±SD. P values refer to variation at the specific time point compared with baseline in MedD versus ConD measured by unpaired Wilcoxon rank- sum 
test.
4w, 4 weeks; 8w, 8 weeks.
was negatively correlated with serum hs- CRP, triglycerides, body 
fat mass, body weight, BMI and urinary carnitine (false discovery 
rate (FDR)<0.05, online supplementary figure 32).
Compared with the baseline values, a significant reduction 
in faecal concentrations of total BAs, including both primary 
and secondary BAs, was observed in the MedD group on the 
MD intervention (figure 5A–C). In addition, faecal deoxycholic 
acid was significantly reduced after 4 (p<0.01) and 8 weeks 
of the intervention (p<0.01) along with faecal lithocholic acid 
(p<0.05 and p<0.01 after 4 and 8 weeks, respectively) within 
the MedD group. Paired Wilcoxon rank- sum tests of faecal 
BA concentrations within each intervention group are shown 
in online supplementary figure 33. A comparison of faecal BA 
concentrations between the MedD and ConD groups after 8 
weeks showed a significant reduction in faecal chenodeoxy-
cholic acid (p<0.05). Accordingly, primary and secondary BAs 
in the faeces were positively linked to proteins and fats from 
animal- based food products, as well as systolic blood pressure, 
BMI, body weight and urinary carnitine (FDR<0.05, online 
supplementary figure 32).
It was also noteworthy that subjects showing the highest reduc-
tion in total BAs and the secondary/primary BA ratio had higher 
baseline levels of Bilophila wadsworthia, which decreased signifi-
cantly after 4 weeks of the intervention (p<0.05, figure 5D).
Despite the twofold increase in dietary fibre intake, no 
changes in faecal concentrations of the main SCFAs acetate, 
butyrate and propionate were observed. However, significant 
reductions in branched- chain fatty acids (BCFAs), such as 
valerate, isovalerate, isobutyrate and 2- methylbutyrate, were 
observed in the faeces of the participants in the MedD group 
over the intervention (figure 6A–D), and these changes mirrored 
the increased intake of plant- based foods (FDR<0.05, online 
supplementary figure 32). Moreover, subjects in the quartile 
of the highest faecal butyrate increase at 4 weeks showed 
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Figure 5 Faecal BA concentrations over the nutritional intervention. Parallel coordinate plot showing variations of faecal (A) total, (B) primary and 
(C) secondary BA concentrations within the MedD group during the intervention. The red triangles indicate mean values, the lines connecting dots are 
used to indicate the same sample at each time point. The significance was tested by applying the post hoc Friedman- Nemenyi test for pairwise test 
of multiple comparisons within each group. (D) In the box plot the relative abundances of Bilophila wadsworthia are compared considering subjects 
falling in the highest quartile (n=16, green) and in the lowest quartile of reduction (n=16, blue) of secondary to primary BAs ratio after 4 weeks of 
treatment. Baseline, 0 weeks; 4w, 4 weeks; 8w, 8 weeks of nutritional intervention. H, highest quartile of reduction; L, lowest quartile of reduction; 
BAs, bile acids.
consistently higher levels of F. prausnitzii and Lachnospiraceae 
taxa (figure 6E,F).
Variation in insulin resistance is linked to baseline levels of 
specific microbial taxa
The Homeostatic Model Assessment for Insulin Resistance 
(HOMA) was calculated as a measure of insulin resistance, and it 
did not change as a result of the intervention (online supplemen-
tary table 1). However, by stratifying the subjects by the varia-
tion in HOMA at 4 weeks compared with baseline, we found 
that subjects who reduced their HOMA on the MD intervention 
had significantly higher baseline levels of several Bacteroides 
species (including B. uniformis and B. vulgatus, p<0.05) and 
lower Prevotella sp. and P. copri levels (p<0.05) than subjects 
who did not exhibit changes in HOMA over time (online supple-
mentary figure 34). Interestingly, P. copri baseline levels showed 
a positive correlation with HOMA variation over the interven-
tion (Spearman’s rho=0.28; p=0.031).
Consistently, when we computed co- abundance groups (CAGs) 
from 16S rRNA gene sequencing analysis, we found significantly 
lower levels of CAG2 (including Prevotella as the most abundant 
genus) in subjects who exhibited reduced HOMA, while levels 
of CAG4 (including Faecalibacterium, Roseburia, Bacteroides, 
other Clostridia) were significantly higher at baseline in partic-
ipants who exhibited reduced HOMA and increased on dietary 
treatment (online supplementary figure 35).
The pangenome of the HOMA and serum hs- CRP- associated 
species (P. copri, F. prausnitzii, B. uniformis, B. vulgatus) was 
further investigated. No clear differences were found according 
to intervention, increase in dietary fibre consumption or decrease 
in HOMA indicating a high subject specificity at the strain level 
(online supplementary figure 36).
DIsCussIOn
This study clearly shows that a change from a Western diet to a 
Mediterranean dietary pattern, without any concomitant change 
in energy intake, macronutrient intake or physical activity, 
modulates individual clinical outcomes, the gut microbiome and 
metabolome after 4 weeks of the intervention in a population 
with cardiometabolic risk due to unhealthy lifestyle.
Each participant in the MedD group received a diet that was 
tailored to his/her habitual energy and macronutrient intake to 
increase the adherence to a typical MD pattern. In other words, 
each subject was instructed on the exact replacements of foods 
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Figure 6 MD intervention determines a reduction of faecal branched- chain fatty acid (BCFA) concentrations and higher levels of Faecalibacterium 
prausnitzii and Lachnospiraceae taxa. Parallel coordinate plot showing variations of (A) valerate, (B) isovalerate, (C) isobutyrate and (D) 
2- methylbutyrate faecal concentrations within MedD population. The red triangles indicate mean values, the lines connecting dots are used to 
indicate the same sample at each time point. The significance was tested by applying the post hoc Friedman- Nemenyi test for pairwise test of 
multiple comparisons within each group. In the box plots, the relative abundances of (E) F. prausnitzii 3 and (F) Lachnospiraceae family are compared 
considering subjects falling in the highest quartile (n=16, violet) and in the lowest quartile (n=16, purple) of faecal butyrate increase after 4 weeks 
of treatment. Statistical differences between groups were determined using Wilcoxon rank- sum tests. Baseline, 0 weeks; 4w, 4 weeks; 8w, 8 weeks of 
intervention. H, highest quartile of increase; L, lowest quartile of increase.
so that specific amounts of Western diet foods were replaced by 
the ones typical of an MD. At the best of our knowledge, this 
approach has not been previously used in intervention studies 
with the MD. This ensured that changes in metabolic markers, 
the gut microbiome and systemic metabolome were not biassed 
by variation in energy intake over the nutritional intervention.
From a clinical perspective, the data show that within a short 
period, consumption of an MD can lower total, LDL- cholesterol 
and HDL- cholesterol in plasma independently of individual 
energy intake and physical activity level. The decrease in LDL- 
cholesterol (by 0.24 mmol/L, −8.3% vs baseline) associated 
with MD in this study is far from the reduction of 1 mmol/L 
that has been indicated as clinically relevant towards a reduction 
in heart disease risk.35 However, it is higher than the average 
reductions (between 0.11 and 0.23 mmol/L) that have been 
found in RCTs comparing meat- based diets with plant- protein- 
based diets including nuts or legumes separately,36 as well as 
those achievable (~0.1 mmol/L) with diets including ellagitan-
nins or anthocyanins.37 Interestingly, in the current study, the 
cholesterol- lowering effect was linearly associated with indi-
vidual adherence to the MD. The relationship between the MD 
index and plasma cholesterol highlights the importance of the 
whole MD pattern and of individual dietary compliance in elic-
iting the hypolipidaemic effect of the MD. We hypothesise that 
the lower dietary intakes of cholesterol (p<0.0001 at 4 and 8 
weeks vs baseline) and saturated fats (p=0.005 at 4 and at 8 
weeks vs baseline) on the MD intervention are the main factors 
responsible for that effect.38
Adherence to the MD was confirmed by comprehensive untar-
geted metabolic profiling of faeces, serum and urine, as well as 
targeted quantification of selected biomarkers. In agreement 
with the MD pattern, we found increased levels of biomarkers 
of wholegrains, legumes, vegetables and nuts, as well as reduced 
concentrations of biomarkers of meat and protein degradation 
products after the MD intervention. These objective measures 
substantiated the dietary records obtained by the Food Frequency 
Questionnaires (FFQ) and the 7- day food diary. The MD- de-
pendent metabolome shift was particularly evident in the urine 
metabolome due to the accumulation of diet- derived metabolites 
of wholegrains, nuts and vegetables. In addition, a range of short- 
chain and medium- chain acylcarnitines were consistently reduced 
in urine following the MD intervention, suggesting a diet- induced 
shift in energy production from beta- oxidation to glycolysis in the 
mitochondria, probably due to an extended period of carbohy-
drate availability due to a steady release from fibre degradation. 
In agreement with these findings, plasma short- chain acylcarni-
tines have been associated with a Western diet39 and have been 
found in higher concentrations in meat eaters than in vegetar-
ians and vegans,40 and urine levels of acylcarnitines were reduced 
with increased wholegrain intake.41 Since acylcarnitines have 
been associated with an increased risk of CVD,42 the reduction 
in acylcarnitines in urine suggests a beneficial MD- induced effect 
on energy metabolism caused by increased intake of dietary fibre.
Overall, the differences in the faecal metabolome associ-
ated with the intervention reflect the replacement of foods of 
animal origin with plant- based foods following MD adherence. 
Oxindole-3- acetic acid, a naturally occurring auxin in plants,43 
as well as the BCAAs leucine and isoleucine and BAs appeared 
to be the main drivers. BAs can be implicated in atherosclerosis, 
diabetes and other cardiometabolic diseases.44 Targeted quanti-
fication of faecal BAs confirmed a significant reduction in their 
concentrations within the MedD group coherently with the 
reduced intake of meat products. In line with these findings, a 
vegan diet has been found to reduce plasma BCAAs and BAs 
in comparison with the levels associated with an animal- based 
diet.45
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High adherence to an MD has also been associated with 
increased faecal concentrations of SCFAs.46 Despite the fact that 
participants doubled their intake of dietary fibre, the MD inter-
vention did not significantly increase the faecal concentrations 
of SCFAs. Faecal SCFA represents the difference between the 
production and absorption or utilisation of SCFAs in the colon 
and rectum. We speculate that a possible improved gut epithelial 
function may have increased SCFAs utilisation and absorption, 
thus hampering the observation of their increase due to higher 
fibre intake. This result was corroborated by recent findings that 
dysbiosis is associated with increased faecal SCFA excretion.47 
The MD decreased faecal concentrations of BCFAs, including 
valerate, which is in agreement with previous studies reporting 
faecal valerate as linked to the consumption of protein- rich 
animal foods46 and not to MD adherence.48 These results 
suggest an altered colonic proteolytic fermentation caused by the 
replacement of animal- based products with plant- based foods. 
This finding was substantiated by microbial- derived proteolytic 
products being reduced with increased MD adherence. An inter-
esting increase in urolithins was observed in the MedD group.
Urolithins are gut microbial metabolites of ellagitannins.49 
Dietary sources of these polyphenols are berries, pomegranate 
and walnuts. However, our data indicated that only nut 
consumption significantly increased over the intervention with 
MD. Therefore, increase in urinary urolithin glucuronides was 
most likely attributed to the intake of walnuts in our study as 
previously reported by others.50 Recently, urolithin A has been 
shown to improve intestinal barrier function in a preclinical 
model51 and has also been associated with lower cardiometa-
bolic risk.52 In addition, urolithin A has been demonstrated to 
be involved in the prevention of prostate,53 endometrial54 and 
breast cancer55 in vitro. Interestingly, in our intervention study, 
urolithin levels were negatively correlated with cardiometabolic 
risk factors such as triglycerides and BMI and these observations 
further corroborate the hypothesis that an MD dietary pattern 
might beneficially impacts human health status through gut 
microbiota metabolism.
It was recently reported that microbiome composition is 
more associated with specific food choices than with nutritional 
patterns, that food–microbe interactions are highly personalised, 
and that these factors might limit the observation of overall 
microbiome responses to specific diets.9 Interestingly, despite 
such insightful evidence, we observed clear microbiome shifts 
following our dietary intervention protocol.
Gut microbial taxonomic and functional composition in our 
isocaloric MD intervention revealed that the overall micro-
bial richness was maintained, which is consistent with recent 
studies showing similar trends after increased consumption of 
wholegrain.28 56 However, we observed that the MD dynamically 
modulates the intestinal microbiome composition and that the 
microbiome variations are proportional to the increase in MD 
adherence rates.
Even though prior studies addressed the link between diet, 
gene richness and inflammation markers,7 28 56–58 intervention 
studies describing variation of the microbial genetic richness 
following an MD dietary pattern have not previously been 
described. Interestingly, here MD improves the inflammatory 
status of individuals experiencing an increase in gut microbiome 
gene richness during controlled energy and modified macronu-
trient intakes, further supporting the idea that MD might be an 
efficient dietary strategy to reduce inflammation.13 59
The MD intervention protocol determined a decline in R. 
torques and R. gnavus. The latter species has been recently 
demonstrated as a proinflammatory species due to secretion of 
a polysaccharide that induces tumour necrosis factor alpha in 
dendritic cells,60 whereas possible involvement of R. torques in 
inflammation remains largely uncertain and is currently based 
on associations.61 62
Subjects with the highest reduction in faecal BAs consistently 
also exhibited reduced relative abundance of Bilophila wadswor-
thia, which was previously linked to higher BA levels,63 animal- 
based and high fat diets, as well as irritable bowel diseases.7 64 This 
decline was accompanied by an increase in several potentially 
beneficial species, including the fibre- degrading F. prausnitzii, 
Roseburia and members of the Clostridiales and Lachnospiraceae 
taxa, linked to butyrate precursor functional pathways. These 
reportedly beneficial species were previously documented for 
their anti- inflammatory properties and their role in the develop-
ment of the intestinal barrier65 66 and were, in the present study, 
found to be boosted by foods recommended as part of a healthy 
MD nutritional pattern.
Our data also show that an MD- tailored dietary intervention 
might be helpful in ameliorating insulin sensitivity in individ-
uals harbouring higher levels of several Bacteroides species and 
lower levels of Prevotella sp. and P. copri. The association of P. 
copri with insulin resistance was already reported by Pedersen 
et al67 and it was recently demonstrated to be strain- dependent 
and correlated with the occurrence of genes involved in BCAA 
biosynthesis.68
These findings are in line with the concept of personalised 
responses of individuals to similar diets, and they are of impor-
tance for clinical practice in the era of precision medicine and 
personalised nutrition.9 12
Taken together, our results indicate that an MD may remodel 
the intestinal microbiome towards a state that promotes meta-
bolic and cardiovascular health. In addition, our observations 
can be useful to plan baseline stratifications of subjects based 
on microbiome composition to select specific metabotypes that 
could be involved in ad hoc nutritional interventions to poten-
tiate the clinical outcomes.
Author affiliations
1Université Paris- saclay, inrae, MgP, Jouy- en- Josas, France
2Department of agricultural sciences, University of naples Federico ii, Portici, italy
3Department of nutrition, exercise and sports, Faculty of science, University of 
copenhagen, Frederiksberg, Denmark
4Task Force on Microbiome studies, University of naples Federico ii, naples, italy
5institute of Food science of cnr, avellino, italy
6Department of clinical Medicine and surgery, University of naples Federico ii, 
naples, italy
Twitter Manolo laiola @hroager, henrik Munch roager @hroager and Danilo 
ercolini @Daniloercolini
Acknowledgements We would like to thank agria spa, Fiammante icab spa, Olio 
Dante spa and Pastificio Di Martino spa for kindly providing foods to be included 
in the food boxes for our participants. The authors would also like to thank cecilie 
Fryland appeldorff, sofie skov Frost and sarah Fleischer Ben soltane (University of 
copenhagen) for excellent technical assistance on ultra- high- performance liquid 
chromatography mass spectrometry (UhPlc- Ms) analyses; sébastien Fromentin, 
Magali Berland, Kévin Da silva and Florence Thirion (MgP Metagenopolis) for their 
distinguished bioinformatical guidance; and Dr Maria assunta gallo and centro 
Diagnostico san ciro (Portici, italy) for their support with the clinical visits.
Contributors The principal investigators (De, Dse and lOD) and the other 
coapplicants (PV) designed the study and obtained funding. The nutritional 
intervention was carried out at the University of naples Federico ii by aar, rg, iM 
and PV. hMr, rF, lOD and PV generated and analysed the metabolomics data. hr 
and BQ generated the metagenomics data, and Ml, VM, FDF, eP and nP analysed 
the microbiome data and performed the statistical analyses. all authors participated 
in the data interpretation; De wrote the paper with contributions by Ml, hMr, PV 
and VM. all authors read, edited and approved the final version of the manuscript.
The corresponding authors attest that all listed authors meet authorship criteria and 
that no others meeting the criteria have been omitted.
copyright.
 o
n
 June 12, 2020 at Kobenhavns Universitets Bibliotek. Protected by
http://gut.bmj.com/
G
ut: first published as 10.1136/gutjnl-2019-320438 on 19 February 2020. Downloaded from 
1267Meslier V, et al. Gut 2020;69:1258–1268. doi:10.1136/gutjnl-2019-320438
Gut microbiota
Funding The study was conducted within the Diet- induced arrangement of the 
gut Microbiome for the improvement of cardiometabolic health (DinaMic) project 
funded within the european Joint Programming initiative “a healthy Diet for a 
healthy life” (JPi hDhl) – Joint action “intestinal Microbiomics”. The DinaMic 
national funding organization are (i) the italian Ministry of education, University and 
research (prot.0000426); (ii) the innovation Fund Denmark (grant # 5195-00001B) 
and (iii) the French national research agency (anr-15- hDiM-0002-04). The study 
was also partially supported by a semper ardens grant to lars Ove Dragsted and the 
Metagenopolis grant anr-11- DPBs-0001.a full list of the DinaMic consortium and 
their affiliations appears in the online supplementary material.
Competing interests none declared.
Patient consent for publication not required.
ethics approval The trial was conducted at the University of naples Federico ii 
and was approved by the related ethics committee (Protocol number: 108/16)
Provenance and peer review not commissioned; externally peer reviewed.
Data availability statement Data are available in a public, open access 
repository. Metagenomic reads generated in this study are available (without 
conditions of reuse) under the accession number PrJeB33500 at the european 
nucleotide archive (ena) in eBi (https://www. ebi. ac. uk/ ena/ data/ view/ PrJeB33500).
Open access This is an open access article distributed in accordance with the 
creative commons attribution non commercial (cc BY- nc 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non- commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited, appropriate credit is given, any changes made indicated, and the use 
is non- commercial. see: http:// creativecommons. org/ licenses/ by- nc/ 4. 0/.
OrCID iDs
henrik Munch roager http:// orcid. org/ 0000- 0002- 2504- 8313
lars Ove Dragsted http:// orcid. org/ 0000- 0003- 0609- 6317
stanislav Dusko ehrlich http:// orcid. org/ 0000- 0002- 7563- 4046
Danilo ercolini http:// orcid. org/ 0000- 0003- 3061- 9560
RefeRences
 1 Kelly JT, Palmer sc, Wai sn, et al. healthy dietary patterns and risk of mortality 
and esrD in cKD: a meta- analysis of cohort studies. Clin J Am Soc Nephrol 
2017;12:272–9.
 2 chiavaroli l, Viguiliouk e, nishi sK, et al. Dash dietary pattern and cardiometabolic 
outcomes: an umbrella review of systematic reviews and meta- analyses. Nutrients 
2019;11:338.
 3 Martínez- gonzález Ma, gea a, ruiz- canela M. The Mediterranean diet and 
cardiovascular health. Circ Res 2019;124:779–98.
 4 Bendall cl, Mayr hl, Opie rs, et al. central obesity and the Mediterranean diet: a 
systematic review of intervention trials. Crit Rev Food Sci Nutr 2018;58:3070–84.
 5 eleftheriou D, Benetou V, Trichopoulou a, et al. Mediterranean diet and its components 
in relation to all- cause mortality: meta- analysis. Br J Nutr 2018;120:1081–97.
 6 cani PD. human gut microbiome: hopes, threats and promises. Gut 
2018;67:1716–25.
 7 David la, Maurice cF, carmody rn, et al. Diet rapidly and reproducibly alters the 
human gut microbiome. Nature 2014;505:559–63.
 8 roager hM, Dragsted lO. Diet-derived microbial metabolites in health and disease. 
Nutr Bull 2019;44:216–27.
 9 Johnson aJ, Vangay P, al- ghalith ga, et al. Daily sampling reveals personalized Diet- 
Microbiome associations in humans. Cell Host Microbe 2019;25:789–802.
 10 Bashiardes s, godneva a, elinav e, et al. Towards utilization of the human genome 
and microbiome for personalized nutrition. Curr Opin Biotechnol 2018;51:57–63.
 11 grosso g, Micek a, godos J, et al. health risk factors associated with meat, fruit and 
vegetable consumption in cohort studies: a comprehensive meta- analysis. PLoS One 
2017;12:e0183787.
 12 De Filippis F, Vitaglione P, cuomo r, et al. Dietary interventions to modulate the 
gut Microbiome- how far away are we from precision medicine. Inflamm Bowel Dis 
2018;24:2142–54.
 13 Bailey Ma, holscher hD. Microbiome- mediated effects of the Mediterranean diet on 
inflammation. Adv Nutr 2018;9:193–206.
 14 harris rP, helfand M, Woolf sh, et al. current methods of the Us preventive services 
Task force: a review of the process. Am J Prev Med 2001;20:21–35.
 15 Blumberg J, heaney rP, huncharek M, et al. evidence- Based criteria in the nutritional 
context. Nutr Rev 2010;68:478–84.
 16 Myles ia. Fast food fever: reviewing the impacts of the Western diet on immunity. 
Nutr J 2014;13:61.
 17 Minihane aM, Vinoy s, russell Wr, et al. low- grade inflammation, diet 
composition and health: current research evidence and its translation. Br J Nutr 
2015;114:999–1012.
 18 Mozaffarian D, hao T, rimm eB, et al. changes in diet and lifestyle and long- term 
weight gain in women and men. N Engl J Med 2011;364:2392–404.
 19 agnoli c, Krogh V, grioni s, et al. a priori- defined dietary patterns are associated with 
reduced risk of stroke in a large italian cohort. J Nutr 2011;141:1552–8.
 20 andersen M- Bs, Kristensen M, Manach c, et al. Discovery and validation of urinary 
exposure markers for different plant foods by untargeted metabolomics. Anal Bioanal 
Chem 2014;406:1829–44.
 21 Barri T, Dragsted lO. UPlc- esi- QTOF/Ms and multivariate data analysis for blood 
plasma and serum metabolomics: effect of experimental artefacts and anticoagulant. 
Anal Chim Acta 2013;768:118–28.
 22 christiansen cB, gabe MBn, svendsen B, et al. The impact of short- chain fatty acids 
on glP-1 and PYY secretion from the isolated perfused rat colon. Am J Physiol 
Gastrointest Liver Physiol 2018;315:g53–65.
 23 hjerpsted JB, Dragsted lO, Tholstrup T. cheese intake lowers plasma cholesterol 
concentrations without increasing bile acid excretion. J Nutr Intermed Metab 
2016;3:12–17.
 24 Plaza Oñate F, le chatelier e, almeida M, et al. MsPminer: abundance- based 
reconstitution of microbial pan- genomes from shotgun metagenomic data. 
Bioinformatics 2019;35:1544–52.
 25 gu Z, eils r, schlesner M. complex heatmaps reveal patterns and correlations in 
multidimensional genomic data. Bioinformatics 2016;32:2847–9.
 26 Pasolli e, Truong DT, Malik F, et al. Machine learning meta- analysis of large 
metagenomic datasets: tools and biological insights. PLoS Comput Biol 
2016;12:e1004977.
 27 Drescher ls, Thiele s, Mensink gBM. a new index to measure healthy food diversity 
better reflects a healthy diet than traditional measures. J Nutr 2007;137:647–51.
 28 roager hM, Vogt JK, Kristensen M, et al. Whole grain- rich diet reduces body weight 
and systemic low- grade inflammation without inducing major changes of the gut 
microbiome: a randomised cross- over trial. Gut 2019;68:83–93.
 29 Keller BO, Wu BTF, li ssJ, et al. hypaphorine is present in human milk in association 
with consumption of legumes. J Agric Food Chem 2013;61:7654–60.
 30 cuparencu cs, andersen M- Bs, gürdeniz g, et al. identification of urinary biomarkers 
after consumption of sea buckthorn and strawberry, by untargeted lc–Ms 
metabolomics: a meal study in adult men. Metabolomics 2016;12:31.
 31 Tulipani s, Urpi- sarda M, garcía- Villalba r, et al. Urolithins are the main urinary 
microbial- derived phenolic metabolites discriminating a moderate consumption of 
nuts in free- living subjects with diagnosed metabolic syndrome. J Agric Food Chem 
2012;60:8930–40.
 32 Dragsted lO. Biomarkers of meat intake and the application of nutrigenomics. Meat 
Sci 2010;84:301–7.
 33 Khakimov B, Poulsen sK, savorani F, et al. new nordic diet versus average 
Danish diet: a randomized controlled trial revealed healthy long- term effects 
of the new nordic diet by gc- Ms blood plasma metabolomics. J Proteome Res 
2016;15:1939–54.
 34 singh a, shannon cP, gautier B, et al. DiaBlO: an integrative approach for identifying 
key molecular drivers from multi- omics assays. Bioinformatics 2019;35:3055–62.
 35 lewington s, Whitlock g, clarke r, et al. Blood cholesterol and vascular mortality by 
age, sex, and blood pressure: a meta- analysis of individual data from 61 prospective 
studies with 55,000 vascular deaths. Lancet 2007;370:1829–39.
 36 guasch- Ferré M, satija a, Blondin sa, et al. Meta- analysis of randomized controlled 
trials of red meat consumption in comparison with various comparison diets on 
cardiovascular risk factors. Circulation 2019;139:1828–45.
 37 garcía- conesa M- T, chambers K, combet e, et al. Meta- analysis of the effects 
of foods and derived products containing ellagitannins and anthocyanins on 
cardiometabolic biomarkers: analysis of factors influencing variability of the individual 
responses. Int J Mol Sci 2018;19:694.
 38 Wolff e, Vergnes M- F, Portugal h, et al. cholesterol- absorber status modifies the lDl 
cholesterol- lowering effect of a Mediterranean- type diet in adults with moderate 
cardiovascular risk factors. J Nutr 2011;141:1791–8.
 39 Bouchard- Mercier a, rudkowska i, lemieux s, et al. The metabolic signature 
associated with the Western dietary pattern: a cross- sectional study. Nutr J 
2013;12:158.
 40 schmidt Ja, rinaldi s, Ferrari P, et al. Metabolic profiles of male meat eaters, fish 
eaters, vegetarians, and vegans from the ePic- Oxford cohort. Am J Clin Nutr 
2015;102:1518–26.
 41 ross aB, Pere- Trépat e, Montoliu i, et al. a whole- grain- rich diet reduces urinary 
excretion of markers of protein catabolism and gut microbiota metabolism in healthy 
men after one week. J Nutr 2013;143:766–73.
 42 guasch- Ferré M, Zheng Y, ruiz- canela M, et al. Plasma acylcarnitines and risk of 
cardiovascular disease: effect of Mediterranean diet interventions. Am J Clin Nutr 
2016;103:1408–16.
 43 Korver ra, Koevoets iT, Testerink c. Out of shape during stress: a key role for auxin. 
Trends Plant Sci 2018;23:783–93.
 44 chávez- Talavera O, Tailleux a, lefebvre P, et al. Bile acid control of metabolism and 
inflammation in obesity, type 2 diabetes, dyslipidemia, and nonalcoholic fatty liver 
disease. Gastroenterology 2017;152:1679–94.
 45 Draper cF, Vassallo i, Di cara a, et al. a 48- hour vegan diet challenge in healthy 
women and men induces a branch- chain amino acid related, health associated, 
metabolic signature. Mol Nutr Food Res 2018;62:1700703.
copyright.
 o
n
 June 12, 2020 at Kobenhavns Universitets Bibliotek. Protected by
http://gut.bmj.com/
G
ut: first published as 10.1136/gutjnl-2019-320438 on 19 February 2020. Downloaded from 
1268 Meslier V, et al. Gut 2020;69:1258–1268. doi:10.1136/gutjnl-2019-320438
Gut microbiota
 46 De Filippis F, Pellegrini n, Vannini l, et al. high- level adherence to a Mediterranean 
diet beneficially impacts the gut microbiota and associated metabolome. Gut 
2016;65:1812–21.
 47 de la cuesta- Zuluaga J, Mueller n, Álvarez- Quintero r, et al. higher fecal short- chain 
fatty acid levels are associated with gut microbiome dysbiosis, obesity, hypertension 
and cardiometabolic disease risk factors. Nutrients 2019;11:51.
 48 Mitsou eK, Kakali a, antonopoulou s, et al. adherence to the Mediterranean diet is 
associated with the gut microbiota pattern and gastrointestinal characteristics in an 
adult population. Br J Nutr 2017;117:1645–55.
 49 cerdá B, Periago P, espín Jc, et al. identification of urolithin a as a metabolite 
produced by human colon microflora from ellagic acid and related compounds. J Agric 
Food Chem 2005;53:5571–6.
 50 garcia- aloy M, hulshof PJM, estruel- amades s, et al. Biomarkers of food intake for 
nuts and vegetable oils: an extensive literature search. Genes Nutr 2019;14:7.
 51 singh r, chandrashekharappa s, Bodduluri sr, et al. enhancement of the gut 
barrier integrity by a microbial metabolite through the nrf2 pathway. Nat Commun 
2019;10:89.
 52 selma MV, gonzález- sarrías a, salas- salvadó J, et al. The gut microbiota 
metabolism of pomegranate or walnut ellagitannins yields two urolithin- 
metabotypes that correlate with cardiometabolic risk biomarkers: comparison 
between normoweight, overweight- obesity and metabolic syndrome. Clin Nutr 
2018;37:897–905.
 53 stanisławska iJ, granica s, Piwowarski JP, et al. The activity of urolithin a and M4 
Valerolactone, colonic microbiota metabolites of polyphenols, in a prostate cancer in 
vitro model. Planta Med 2019;85:118–25.
 54 Zhang W, chen J- h, aguilera- Barrantes i, et al. Urolithin a suppresses the proliferation 
of endometrial cancer cells by mediating estrogen receptor-α-dependent gene 
expression. Mol Nutr Food Res 2016;60:2387–95.
 55 Teixeira ll, costa gr, Dörr Fa, et al. Potential antiproliferative activity of polyphenol 
metabolites against human breast cancer cells and their urine excretion pattern in 
healthy subjects following acute intake of a polyphenol- rich juice of grumixama 
(eugenia brasiliensis lam.). Food Funct 2017;8:2266–74.
 56 haro c, Montes- Borrego M, rangel- Zúñiga Oa, et al. Two healthy diets modulate gut 
microbial community improving insulin sensitivity in a human obese population. J Clin 
Endocrinol Metab 2016;101:233–42.
 57 haro c, garcia- carpintero s, alcala- Diaz JF, et al. The gut microbial community in 
metabolic syndrome patients is modified by diet. J Nutr Biochem 2016;27:27–31.
 58 Vanegas sM, Meydani M, Barnett JB, et al. substituting whole grains for refined 
grains in a 6- wk randomized trial has a modest effect on gut microbiota and immune 
and inflammatory markers of healthy adults. Am J Clin Nutr 2017;105:635–50.
 59 Vitaglione P, Mennella i, Ferracane r, et al. Whole- grain wheat consumption reduces 
inflammation in a randomized controlled trial on overweight and obese subjects with 
unhealthy dietary and lifestyle behaviors: role of polyphenols bound to cereal dietary 
fiber. Am J Clin Nutr 2015;101:251–61.
 60 henke MT, Kenny DJ, cassilly cD, et al. Ruminococcus gnavus, a member of the 
human gut microbiome associated with crohn’s disease, produces an inflammatory 
polysaccharide. Proc Natl Acad Sci U S A 2019;116:12672–7.
 61 le chatelier e, nielsen T, Qin J, et al. richness of human gut microbiome correlates 
with metabolic markers. Nature 2013;500:541–6.
 62 Brahe lK, le chatelier e, Prifti e, et al. specific gut microbiota features and metabolic 
markers in postmenopausal women with obesity. Nutr Diabetes 2015;5:e159.
 63 Devkota s, Wang Y, Musch MW, et al. Dietary- fat- induced taurocholic acid promotes 
pathobiont expansion and colitis in il10-/- mice. Nature 2012;487:104–8.
 64 natividad JM, lamas B, Pham hP, et al. Bilophila wadsworthia aggravates high fat 
diet induced metabolic dysfunctions in mice. Nat Commun 2018;9:2802.
 65 sokol h, Pigneur B, Watterlot l, et al. Faecalibacterium prausnitzii is an anti- 
inflammatory commensal bacterium identified by gut microbiota analysis of crohn 
disease patients. Proc Natl Acad Sci U S A 2008;105:16731–6.
 66 Vital M, Karch a, Pieper Dh. colonic butyrate- producing communities in humans: an 
overview using omics data. mSystems 2017;2:e00130–17.
 67 Pedersen hK, gudmundsdottir V, nielsen hB, et al. human gut microbes impact host 
serum metabolome and insulin sensitivity. Nature 2016;535:376–81.
 68 De Filippis F, Pasolli e, Tett a, et al. Distinct genetic and functional traits of human 
intestinal Prevotella copri strains are associated with different habitual diets. Cell Host 
Microbe 2019;25:444–53.
copyright.
 o
n
 June 12, 2020 at Kobenhavns Universitets Bibliotek. Protected by
http://gut.bmj.com/
G
ut: first published as 10.1136/gutjnl-2019-320438 on 19 February 2020. Downloaded from 
